JPRN-jRCT1080223548已完成3 期
A Randomized, Open-Label, Controlled, Phase III Trial Comparing guaranteed Mesenchymal Stem Cell 1 (gMSC1) versus Microfracture (MFx) in Patients with Symptomatic Articular Cartilage Defects or Osteochondritis Dissecans in the Knee
TWOCELLS COMPANY, LIMITED0 个研究点目标入组 70 人开始时间: 2017年5月31日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 <= 59age old（—）
- 性别
- All
入选标准
- •1) Articular cartilage defects / osteochondritis dissecans (OCD) in the knee
- •2) Index defects are International Cartilage Repair Society (ICRS) Articular cartilage injury classification Grade 3 or 4 cartilage defects or index defects are Nelson Grade 3 or 4 OCD lesions
排除标准
- •1) Articular cartilage defects / osteochondritis dissecans (OCD) in the both knees
- •2) Osteoarthritis (narrowing of medial joint space>=1/3 compared to normal)
- •3) Ligament injury needs surgical treatment, or less than 4 weeks between surgical treatment for ligament injury and gMSC1 transplantation or MFx
- •4) Meniscus injury needs surgical treatment, or less than 6 weeks between surgical treatment for meniscus injury and gMSC1 transplantation or MFx. Regardless of the timing of surgical treatment for meniscus injury, meniscal resection of 50% and over
- •5) Less than 1 year between surgical treatment except debridement for the lesions and gMSC1 transplantation or MFx
研究者
相似试验
进行中（未招募）
3 期
Study in Patients with surgically non removeable Urothelial Cancer with Durvalumab in Combination with Chemotherapy and Durvalumab in Combination with Tremelimumab and Chemotherapy Versus Chemotherapy AloneCTRI/2019/07/020184AstraZeneca AB
进行中（未招募）
1 期
Study of First Line MEDI4736 with or without Tremelimumab versus Standard of Care Chemotherapy in Advanced Unresectable Urothelial CancerEUCTR2015-001633-24-NLAstraZeneca AB1,005
招募中
1 期
A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or urinary systemPatients with Unresectable Locally Advanced or Metastatic Urothelial CancerMedDRA version: 20.0Level: PTClassification code: 10005003Term: Bladder cancer Class: 100000004864CTIS2024-510976-19-00AstraZeneca AB1,274
进行中（未招募）
1 期
Study of First Line MEDI4736 with or without Tremelimumab versus Standard of Care Chemotherapy in Advanced Unresectable Urothelial CancerAdult patients (age =18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.MedDRA version: 21.0Level: LLTClassification code 10022880Term: Invasive bladder cancer stage IVSystem Organ Class: 100000004864EUCTR2015-001633-24-ATAstraZeneca AB1,185
招募中
3 期
ILEnresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial CancerJPRN-jRCT2080224099AstraZeneca